Akorn second quarter revenue grows 59 percent to $32.

The Company has completed development focus on 13 additional products with a mixed annual market size of approximately $1.3 billion and expects to file these products with the FDA shortly.. Akorn second quarter revenue grows 59 percent to $32.1 million Akorn, Inc. , a niche specialty pharmaceutical company, reported financial results for the second quarter of 2011 today. The Company also individually announced that it has entered into an agreement to get a minority possession in Westborough, MA, centered Aciex Therapeutics Inc., an ophthalmic drug development business with a focus on developing novel therapeutics to treat front-of-eye diseases.Finally, the technical complexity of establishing criteria is challenging. As Koppel explains, something ostensibly simple even, such as blood-pressure measurement, can get lost in translation because of the modifiers accompanying the numbers: standing, seated, preinjection, labile, non-compliant. So imagine a common language for MRI reports or operative notes. Although industry influence is indisputable, this description conflicts with the impression I acquired from Judy Faulkner, ceo of EHR maker Epic Systems, who advocates for government-created specifications. Whether other vendors are prepared to make their products interoperable, government frequently overrides industry’s financial interests to achieve a larger public good. I’m all for those who have vision problems.